Dialog Box

Trikafta update

Trikafta® (elexacaftor/tezacaftor/ivacaftor) is a new triple combination therapy that may benefit many people living with CF.  Trikafta® was not recommended for reimbursement by the Pharmaceutical Benefits Advisory Committee (PBAC) during its April 2021 meeting.

What happened the April PBAC meeting?

Here is a snapshot of the PBAC’s rationale for deferring Trikafta. We are saddened by this delay in securing access to an extremely important CF drug and will be fighting for Immediate Compassionate Access while negotiations drag on

How you can help?

The PBAC have a website where people can provide comments from a personal, or group, perspective that will be considered when they are reviewing Trikafta®.

When making comments through the website (portal), think about:

  • How CF affects your quality of life?
  • What would you most like to see from this treatment or expect will happen if you do take it?
  • If you are taking Trikafta® , what was your experience of any benefits or side effects?
What is Trikafta®?

Elexacaftor/tezacaftor/ivacaftor, or Trikafta®, is a type of medication known as a CFTR modulator. CFTR modulators work differently to other medications for CF. They work by correcting the malfunctioning protein that causes CF. In doing so, these medications directly address the cause of CF, rather than just the symptoms. They are not a cure, but they help the body’s cells to function more normally.

Trikafta® is a triple combination therapy. It has three active ingredients, elexacaftor, tezacaftor and ivacaftor. Elexacaftor and tezacaftor help the F508del-CFTR protein change to the correct shape, move to the surface of the cell and stay there longer. Ivacaftor then helps to open the channel so that chloride can flow in and out of the cells.

Read more about treatment 

09 June 2021
Category: News